इट्राकोनाज़ोल और विन्क्रिस्टिन का इंटरैक्शन

Therefore, the concomitant use of strong CYP3A inhibitors with vincristine sulfate should be avoided.

Therefore, the concomitant use of P-gp inhibitors or inducers should be avoided.

Concurrent administration of vincristine sulfate with itraconazole or fluconazole (known inhibitors of the CYP3A metabolic pathway) has been reported to cause an earlier onset and/or an increased severity of neuromuscular side effects (see ADVERSE REACTIONS ).

Patients should be frequently monitored for adverse reactions with concomitant use of moderate CYP3A inhibitors (e.g., fluconazole) with vincristine sulfate.